The Evolving Role of TKIs in First-line Treatment of Advanced HCC
In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.
Decera Clinical Education Oncology Podcast · Josep M Llovet MD PhD FAASLD, Prof Markus Peck-Radosavljevic MD MBA, Markus Peck-Radosavljevic
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:
- Atezolizumab plus bevacizumab as the current standard of care
- Contraindications to atezolizumab plus bevacizumab
- The current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinoma
- Ongoing clinical trials in the first-line setting
Presenters:
Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, NY
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain
Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine, Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin and Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria
Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.